Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 1Suspended 1Recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Lymphoma, Large B-Cell, Diffuse 36Multiple Myeloma 33Burkitt Lymphoma 32Lymphoma 30Leukemia, Myeloid, Acute 29Lymphoma, Non-Hodgkin 28Recurrence 26Breast Neoplasms 26Lymphoma, B-Cell 23Neoplasms 22Myelodysplastic Syndromes 20Lymphoma, Follicular 20Leukemia, Lymphocytic, Chronic, B-Cell 20Hodgkin Disease 17Triple Negative Breast Neoplasms 16Leukemia 16Ovarian Neoplasms 15Hematologic Neoplasms 15Melanoma 14Neuroblastoma 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Mantle-Cell 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Pancreatic Neoplasms 11Leukemia, Biphenotypic, Acute 10Sarcoma 9Neoplasm Metastasis 9Lymphoma, B-Cell, Marginal Zone 9Leukemia, Myelomonocytic, Chronic 9

Interventions

Cyclophosphamide 3Vincristine 2Prednisone 2Etoposide 2Doxorubicin 2tazemetostat 1pembrolizumab 1fludarabine 1etoposide phosphate 1duvelisib 1Prednisolone 1Melphalan 1Cytarabine 1Carmustine 1Azacitidine 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Enteropathy-Associated T-Cell Lymphoma × Cyclophosphamide × 90 days × Clear all
NCT04803201 2026-06-02

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Alliance for Clinical Trials in Oncology

Phase 2 Suspended
170 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT07055477 2026-05-22

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
60 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡